Roivant Sciences
American pharmaceuticals company
Follow Roivant Sciences on Notably News to receive short updates to your email — rarely!
| December 2023 | Roche completed the acquisition of Telavant from Roivant for $7.1 billion upfront and a near-term milestone payment of $150 million. |
| December 2022 | Roivant and Pfizer announced a third partnership to create a new Vant focused on developing TL1A drug candidates for inflammatory and fibrotic diseases. |
| June 2022 | Roivant and Pfizer unveiled Priovant Therapeutics, with Pfizer holding a 25% equity ownership interest. |
| October 2021 | Roivant merged with special-purpose acquisition company Montes Archimedes Acquisition Corp. to become listed on the Nasdaq. |
| September 2021 | Established Priovant Therapeutics through a transaction with Pfizer, licensing global development rights for brepocitinib. |
| February 2021 | Roivant acquired Silicon Therapeutics, a small-molecule drug designer and computational physics platform, for $450 million in Roivant equity. |
| January 2021 | Vivek Ramaswamy stepped down as CEO, with Matt Gline becoming the new CEO. |
| October 2020 | Datavant, co-founded with Travis May, announced fundraising from Roivant, Transformation Capital, Johnson & Johnson, and Cigna to link disparate healthcare datasets. |
| April 2020 | Began administration of gimsilumab to COVID-19 patients in the United States. |
| April 2020 | Roivant dosed the first patient in a clinical study evaluating gimsilumab for COVID-19 patients. Datavant also announced its technology was being used to create a pro bono COVID-19 research database. |
| March 2020 | Announced the development of gimsilumab, an anti-GM-CSF monoclonal antibody, to prevent and treat acute respiratory distress syndrome (ARDS) in COVID-19 patients. |
| December 2019 | Roivant formed a $3 billion partnership with Sumitomo Dainippon Pharma, transferring ownership stakes in five subsidiaries to Sumitovant Biopharma. |
| July 2018 | Immunovant was launched to develop therapies for autoimmune diseases, with a lead candidate IMVT-1401 targeting myasthenia gravis, Graves' ophthalmopathy, and warm antibody autoimmune hemolytic anemia. |
| June 2018 | Roivant laid off 67 employees and reassigned 130 to various subsidiaries as part of a strategic workforce reorganization. |
| 2017 | Roivant partnered with the private equity arm of Chinese state-owned CITIC Group to form Sinovant. |
| 2014 | Vivek Ramaswamy founded Roivant Sciences, initially focusing on in-licensing drug candidates and creating subsidiaries for distinct therapeutic areas. |
This contents of the box above is based on material from the Wikipedia article Roivant Sciences, which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.